To include your compound in the COVID-19 Resource Center, submit it here.

Merck acquires cancer play Rigontec

Merck & Co. Inc. (NYSE:MRK) is acquiring immuno-oncology company Rigontec GmbH (Munich, Germany). Rigontec will receive €115 million ($136.8 million) in cash up front and is eligible for up to €349 million ($415.2

Read the full 336 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE